Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00589706 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of Adjuvant Use of Anti-Epidermal Growth Factor Receptor EGFR-425 in High Grade Gliomas
A Phase 2 study of Gliomas, sponsored by Drexel University College of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT00589706: Completed Phase 2 study of Gliomas, sponsored by Drexel University College of Medicine.
NCT00589706 is a Phase 2 study of Gliomas that has completed, run by Drexel University College of Medicine. The registered enrollment target is 11 participants, below the 43-participant average among 3 other Gliomas trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00589706, a Phase 2 study of Gliomas, has completed, sponsored by Drexel University College of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
Data from the wistar institute indicated that this anti-body labeled with iodine-125 would localized in the tumor cells of high grade gliomas of the brain. the project combines surgery, radiation therapy, chemotherapy with the labeled antibody in a prospective phase II trial in this disease entity.
Primary Outcome
Potential benefits may include improved long-term survival. All or part of your tumor may be destroyed. You may experience relief of symptoms related to your tumor.
Conditions Studied
Interventions
- DRUG MAb-425
Study Locations (1)
Pennsylvania
- Hahneman Hospital - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 1985-01 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
What the finished NCT00589706 record still lists
NCT00589706 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 43-participant average among 3 other Gliomas trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Gliomas appearing as the primary indexed condition, and to 1 intervention - of which MAb-425 is the first listed.
NCT00589706 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00589706 about?
NCT00589706 is a clinical study titled "A Phase II Study of Adjuvant Use of Anti-Epidermal Growth Factor Receptor EGFR-425 in High Grade Gliomas". Data from the wistar institute indicated that this anti-body labeled with iodine-125 would localized in the tumor cells of high grade gliomas of the brain. the project combines surgery, radiation therapy, chemotherapy with the labeled antibody in a prospective phase II trial in this disease entity.
What is the current status of trial NCT00589706?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 1985-01. Estimated completion is 2012-12.
What conditions does trial NCT00589706 study?
This clinical trial studies the following conditions: Gliomas.
What interventions are being tested in trial NCT00589706?
The interventions under investigation include: MAb-425 (DRUG).
Who is sponsoring clinical trial NCT00589706?
This trial is sponsored by Drexel University College of Medicine, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00589706 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gliomas
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia